Association of Time to ICI Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma
Clin Genitourin Cancer 2022 Dec 01;20(6)558-567, R Talukder, D Makrakis, GI Lin, LN Diamantopoulos, S Dawsey, S Gupta, L Carril-Ajuria, D Castellano, I de Kouchkovsky, T Jindal, VS Koshkin, JJ Park, A Alva, MA Bilen, TF Stewart, RR McKay, N Tripathi, N Agarwal, N Vather-Wu, Y Zakharia, R Morales-Barrera, ME Devitt, A Cortellini, CAM Fulgenzi, DJ Pinato, A Nelson, CJ Hoimes, K Gupta, BA Gartrell, A Sankin, A Tripathi, R Zakopoulou, A Bamias, J Murgic, A Fröbe, A Rodriguez-Vida, A Drakaki, S Liu, E Lu, V Kumar, GD Lorenzo, M Joshi, P Isaacsson-Velho, LA Buznego, I Duran, M Moses, P Barata, G Sonpavde, JL Wright, EY Yu, RB Montgomery, AC Hsieh, P Grivas, AR KhakiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.